ClinicalTrials.gg
CompletedNCT03809429BEYONDUpdated May 13, 2024Results posted

Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)

A Phase 3 interventional study of FE 999049 + GnRH agonist (GONAPEPTYL) and FE 999049 + GnRH antagonist (CETROTIDE) in Infertility, Female, sponsored by Ferring Pharmaceuticals. Completed at 16 sites in 7 countries. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-05-13.

Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
437
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Infertility, Female with a site in Israel — none open to participants now, none under way, none of them phase 3. Infertility, Female · Israel.

Started
2019
with 1 other
Phase 3
2 of 12
none open now
Registered
9th of 12
by date
Lead sponsor
2 of 12
Ferring Pharmaceuticals

Among the 12 studies in Infertility, Female with a site in Israel, this one is one of 2 that started in 2019, is one of 2 in phase 3, and was the 9th registered.

Infertility, Female

552 studies on the registry are indexed under Infertility, Female; 135 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

None of the 12 studies in Infertility, Female with a site in Israel is open now. The open studies under Infertility, Female, anywhere →

Who these studies take

Of the 90 Infertility, Female studies recruiting now, 11 (12%) set no upper age limit and 79 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Infertility, Female with a site in Israel as a file.
02

Study summary

To compare the efficacy and safety of FE 999049 (follitropin delta) and its personalized dosing algorithm in controlled ovarian stimulation for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) using a long gonadotropin-releasing hormone (GnRH) agonist protocol versus a short GnRH antagonist protocol.

03

Conditions studied

  • Infertility, Female

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infertile women aged 18-40 undergoing their first IVF/ICSI cycle that are in good physical and mental health and that have been diagnosed with problems in the fallopian tubes, mild endometriosis or have partners with decreased sperm quality.
  • The participants must have a regular menstrual cycle, a normal uterus and 2 normal ovaries.
  • The allowed is 17.5-32 Kg/m\^2.

Exclusion criteria

Exclusion Criteria:

  • Women with very high ovarian reserve, strong preference for either treatment, severe endometriosis, history of repeated miscarriage, couples with known problems in the chromosomes, history or high risk of producing blood cloths, women known to have chronic diseases, women recently participating in trials with non-registered drugs.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
437 participants (actual)

Study arms

  • Experimental
    FE 999049 + GnRH agonist (GONAPEPTYL)

    Drug: FE 999049 + GnRH agonist (GONAPEPTYL)

  • Active comparator
    FE 999049 + GnRH antagonist (CETROTIDE)

    Drug: FE 999049 + GnRH antagonist (CETROTIDE)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Oocytes Retrieved

    The number of oocytes retrieved was recorded at the oocyte retrieval visit.

    Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)

Secondary outcomes

  1. Proportion of Subjects With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response

    For each participant, the reason for cycle cancellation was recorded

    Time frame: At end-of-stimulation (up to 20 days)

  2. Proportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS)

    For each participant, the reason for blastocyst transfer cancellation was recorded.

    Time frame: At end of transfer (up to 4 weeks)

  3. Number of Follicles

    The total number of follicles and the number of follicles per size category will be reported

    Time frame: On stimulation day 6 and at end-of-stimulation (up to 20 days)

  4. Proportion of Subjects With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved

    Grouped according to number of oocytes

    Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)

  5. Number of Metaphase II Oocytes

    Only applicable for those inseminated using ICSI

    Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)

  6. Fertilization Rate

    Measured by the number of pronuclei. Fertilized oocytes with 2 pronuclei were regarded as correctly fertilized

    Time frame: On day 1 after oocyte retrieval (up to 23 days after start of stimulation)

  7. Number of Embryos

    The number of embryos (total and good-quality) was reported. Embryo quality is determined by combined assessment of cleavage stage (number of blastomeres/compaction status) and embryo morphology parameters

    Time frame: On day 3 after oocyte retrieval (up to 25 days after start of stimulation)

  8. Number of Blastocysts

    The number of blastocysts (total and good-quality) was reported. Blastocyst quality is assessed by blastocyst expansion and hatching status, blastocyst inner cell mass grading, and trophectoderm grading. The scoring is based on the classification system by Gardner and Schoolcraft, with additional categories for inner cell mass (degenerative or no inner cell mass) and trophectoderm (degenerative or very large cells)

    Time frame: On day 5 after oocyte retrieval (up to 27 days after start of stimulation)

  9. Circulating Concentrations of Follicle-stimulating Hormone (FSH)

    Blood samples for analysis of circulating concentrations of FSH were drawn.

    Time frame: On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation)

  10. Circulating Concentrations of Luteinizing Hormone (LH)

    Blood samples for analysis of circulating concentrations of LH were drawn

    Time frame: On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation)

  11. Circulating Concentrations of Estradiol

    Blood samples for analysis of circulating concentrations of estradiol were drawn

    Time frame: On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation)

  12. Circulating Concentrations of Progesterone

    Blood samples for analysis of circulating concentrations of progesterone were drawn

    Time frame: On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation)

  13. Circulating Concentrations of Inhibin B

    Blood samples for analysis of circulating concentrations of Inhibin B were drawn

    Time frame: On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation)

  14. Total Gonadotropin Dose

    Calculated by start dates, end dates and daily dose of investigational medicinal product

    Time frame: Up to 20 days

  15. Number of Stimulation Days

    Calculated by start dates and end dates

    Time frame: Up to 20 days

  16. Positive Beta Human Chorionic Gonadotropin (βhCG) Rate

    Defined as positive serum βhCG test

    Time frame: 13-15 days after transfer (up to approximately 1.5 months after start of stimulation)

  17. Implantation Rate

    Defined as the number of gestational sacs after transfer divided by number of blastocysts transferred

    Time frame: 5-6 weeks after transfer (up to approximately 2.5 months after start of stimulation)

  18. Clinical Pregnancy Rate

    Defined as at least one gestational sac

    Time frame: 5-6 weeks after transfer (up to approximately 2.5 months after start of stimulation)

  19. Vital Pregnancy Rate

    Defined as at least one intrauterine gestational sac with fetal heart beat

    Time frame: 5-6 weeks after transfer (up to approximately 2.5 months after start of stimulation)

  20. Ongoing Pregnancy Rate

    At least one intrauterine viable fetus

    Time frame: 10-11 weeks after transfer (up to approximately 4 months after start of stimulation)

  21. Ongoing Implantation Rate

    Defined as number of intrauterine viable fetuses divided by the number of blastocysts transferred

    Time frame: 10-11 weeks after transfer (up to approximately 4 months after start of stimulation)

  22. Proportion of Subjects With Early OHSS (Including OHSS of Moderate/Severe Grade)

    Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe.

    Time frame: Up to 9 days after triggering of final follicular maturation

  23. Proportion of Subjects With Late OHSS (Including OHSS of Moderate/Severe Grade)

    Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe.

    Time frame: >9 days after triggering of final follicular maturation

  24. Frequency of Adverse Events

    Any untoward medical occurrence

    Time frame: From time of signing informed consent until the end-of-trial (approximately 7 months)

  25. Intensity of Adverse Events

    Categorized as mild, moderate or severe

    Time frame: From time of signing informed consent until the end-of-trial (approximately 7 months)

  26. Technical Malfunctions of the Pre-filled Injection Pen

    Incidences of technical malfunctions of the pre-filled injection pen were recorded

    Time frame: Up to 20 days

07

Results

Posted May 13, 2024

Participant flow

The trial was opened for recruitment in April 2019, and participants were assessed at 16 investigational sites in 7 countries between May 2019 and Feb 2022.

Participant flow — Overall Study
MilestoneFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Started220215
Completed192195
Not completed2820
Withdrew: Withdrawal by subject73
Withdrew: Adverse event69
Withdrew: Covid-1931
Withdrew: Participant was discontinued by investigator127

Outcome measures

PrimaryNumber of Oocytes Retrieved

The number of oocytes retrieved was recorded at the oocyte retrieval visit.

Time frame:
On day of oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Mean · Oocytes
Number of Oocytes Retrieved
OocytesFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Number of Oocytes Retrieved11.1 ± 5.99.6 ± 5.5
Statistical analysis
  • FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE) · Negative binomial regression · p = 0.0185 · Difference: 1.31 · 95% CI 0.22 to 2.40Negative binomial regression model with treatment, age strata, and AMH group as factors.
SecondaryProportion of Subjects With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response

For each participant, the reason for cycle cancellation was recorded

Time frame:
At end-of-stimulation (up to 20 days)
Reported as:
Number · participants
Proportion of Subjects With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response
participantsFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Excessive response23
Poor response13
Other reason11
SecondaryProportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS)

For each participant, the reason for blastocyst transfer cancellation was recorded.

Time frame:
At end of transfer (up to 4 weeks)
Reported as:
Number · participants
Proportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS)
participantsFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Transfer cancellation2730
Reason for transfer cancellation: Adverse Event58
Reason for transfer cancellation: Risk of OHSS11
Reason for transfer cancellation: No blastocyst1318
Reason for transfer cancellation: COVID-1931
Reason for transfer cancellation: Other reason52
SecondaryNumber of Follicles

The total number of follicles and the number of follicles per size category will be reported

Time frame:
On stimulation day 6 and at end-of-stimulation (up to 20 days)
Reported as:
Mean · Number of follicles
Number of Follicles
Number of folliclesFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Total number of follicles at Stimulation Day 615.2 ± 6.314.9 ± 6.3
Follicles >= 10 mm at Stimulation Day 64.6 ± 4.37.1 ± 3.6
Follicles >= 12 mm at Stimulation Day 61.6 ± 2.73.8 ± 2.9
Total number of follicles at End-of-stimulation visit18.3 ± 7.117.1 ± 8.0
Follicles >= 10 mm at End-of-stimulation visit14.8 ± 6.413.3 ± 6.1
Follicles >= 12 mm at End-of-stimulation visit12.2 ± 5.310.9 ± 5.1
Follicles >= 15 mm at End-of-stimulation visit7.9 ± 3.77.2 ± 3.3
Follicles >= 17 mm at End-of-stimulation visit4.8 ± 2.14.6 ± 2.0
Statistical analysis
  • FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE) · Negative binomial regression · p = 0.0281 · Difference: 1.14 · 95% CI 0.12 to 2.15Negative binomial regression model with treatment, age strata, and AMH group as factors.
  • FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE) · Negative binomial regression · p = 0.0258 · Difference: 0.99 · 95% CI 0.12 to 1.86Negative binomial regression model with treatment, age strata, and AMH group as factors.
  • FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE) · Negative binomial regression · p = 0.0672 · Difference: 0.58 · 95% CI -0.04 to 1.20Negative binomial regression model with treatment, age strata, and AMH group as factors.
  • FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE) · Negative binomial regression · p = 0.3390 · Difference: 0.21 · 95% CI -0.22 to 0.63Negative binomial regression model with treatment, age strata, and AMH group as factors.
SecondaryProportion of Subjects With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved

Grouped according to number of oocytes

Time frame:
On day of oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Count of participants · Participants
Proportion of Subjects With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved
ParticipantsFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
<4 Oocytes Retrieved1326
4-7 Oocytes Retrieved4756
8-14 Oocytes Retrieved8482
15-19 Oocytes Retrieved4229
>=20 Oocytes Retrieved1611
SecondaryNumber of Metaphase II Oocytes

Only applicable for those inseminated using ICSI

Time frame:
On day of oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Mean · MII oocytes
Number of Metaphase II Oocytes
MII oocytesFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Number of Metaphase II Oocytes9.2 ± 4.87.9 ± 4.7
Statistical analysis
  • FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE) · Negative binomial regression · p = 0.0962 · Difference: 1.11 · 95% CI -0.20 to 2.41Negative binomial regression model with treatment, age strata, and AMH group as factors.
SecondaryFertilization Rate

Measured by the number of pronuclei. Fertilized oocytes with 2 pronuclei were regarded as correctly fertilized

Time frame:
On day 1 after oocyte retrieval (up to 23 days after start of stimulation)
Reported as:
Mean · percentage of fertilized oocytes
Fertilization Rate
percentage of fertilized oocytesFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Fertilization Rate53.8 ± 24.154.4 ± 26.8
SecondaryNumber of Embryos

The number of embryos (total and good-quality) was reported. Embryo quality is determined by combined assessment of cleavage stage (number of blastomeres/compaction status) and embryo morphology parameters

Time frame:
On day 3 after oocyte retrieval (up to 25 days after start of stimulation)
Reported as:
Mean · Embryos
Number of Embryos
EmbryosFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Total number of embryos5.7 ± 3.95.0 ± 3.9
Number of good-quality embryos4.0 ± 3.23.9 ± 3.3
Statistical analysis
  • FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE) · Negative binomial regression · p = 0.1894 · Difference: 0.51 · 95% CI -0.25 to 1.27Negative binomial regression model with treatment, age strata, and AMH group as factors.
  • FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE) · Negative binomial regression · p = 0.9361 · Difference: -0.03 · 95% CI -0.68 to 0.63Negative binomial regression model with treatment, age strata, and AMH group as factors.
SecondaryNumber of Blastocysts

The number of blastocysts (total and good-quality) was reported. Blastocyst quality is assessed by blastocyst expansion and hatching status, blastocyst inner cell mass grading, and trophectoderm grading. The scoring is based on the classification system by Gardner and Schoolcraft, with additional categories for inner cell mass (degenerative or no inner cell mass) and trophectoderm (degenerative or very large cells)

Time frame:
On day 5 after oocyte retrieval (up to 27 days after start of stimulation)
Reported as:
Mean · Blastocysts
Number of Blastocysts
BlastocystsFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Total Number of blastocysts3.8 ± 3.13.3 ± 2.9
Number of good-quality blastocysts2.3 ± 2.32.1 ± 2.2
Statistical analysis
  • FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE) · Negative binomial regression · p = 0.2025 · Difference: 0.37 · 95% CI -0.20 to 0.94Negative binomial regression model with treatment, age strata, and AMH group as factors.
  • FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE) · Negative binomial regression · p = 0.5946 · Difference: 0.12 · 95% CI -0.31 to 0.54Negative binomial regression model with treatment, age strata, and AMH group as factors.
SecondaryCirculating Concentrations of Follicle-stimulating Hormone (FSH)

Blood samples for analysis of circulating concentrations of FSH were drawn.

Time frame:
On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Mean · IU/L
Circulating Concentrations of Follicle-stimulating Hormone (FSH)
IU/LFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Stimulation Day 615.5 ± 4.316.7 ± 4.5
End-of-stimulation16.2 ± 4.415.8 ± 4.0
Oocyte retrieval9.4 ± 2.89.8 ± 2.9
SecondaryCirculating Concentrations of Luteinizing Hormone (LH)

Blood samples for analysis of circulating concentrations of LH were drawn

Time frame:
On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Mean · IU/L
Circulating Concentrations of Luteinizing Hormone (LH)
IU/LFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Stimulation Day 61.5 ± 0.95.6 ± 6.0
End-of-stimulation1.8 ± 0.91.8 ± 1.5
Oocyte retrieval0.2 ± 0.22.0 ± 2.1
SecondaryCirculating Concentrations of Estradiol

Blood samples for analysis of circulating concentrations of estradiol were drawn

Time frame:
On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Mean · pmol/L
Circulating Concentrations of Estradiol
pmol/LFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Stimulation Day 61190.1 ± 1101.22675.8 ± 1544.3
End-of-stimulation7542.7 ± 4106.86487.7 ± 3960.2
Oocyte retrieval3485.1 ± 2129.03163.5 ± 1865.0
SecondaryCirculating Concentrations of Progesterone

Blood samples for analysis of circulating concentrations of progesterone were drawn

Time frame:
On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Mean · nmol/L
Circulating Concentrations of Progesterone
nmol/LFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Stimulation Day 61.8 ± 1.02.6 ± 1.5
End-of-stimulation3.1 ± 1.43.5 ± 2.0
Oocyte retrieval25.9 ± 12.926.0 ± 13.2
SecondaryCirculating Concentrations of Inhibin B

Blood samples for analysis of circulating concentrations of Inhibin B were drawn

Time frame:
On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Mean · pg/mL
Circulating Concentrations of Inhibin B
pg/mLFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Stimulation Day 6690.4 ± 419.1808.2 ± 428.5
End-of-stimulation1032.6 ± 605.2938.1 ± 570.0
Oocyte retrieval416.6 ± 253.9389.0 ± 226.6
SecondaryTotal Gonadotropin Dose

Calculated by start dates, end dates and daily dose of investigational medicinal product

Time frame:
Up to 20 days
Reported as:
Mean · ug
Total Gonadotropin Dose
ugFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Total Gonadotropin Dose112.2 ± 28.996.5 ± 26.0
Statistical analysis
  • FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE) · ANOVA · p = <0.0001 · Difference: 16.94 · 95% CI 12.13 to 21.74ANOVA model with treatment, age strata, and AMH group as factors.
SecondaryNumber of Stimulation Days

Calculated by start dates and end dates

Time frame:
Up to 20 days
Reported as:
Mean · Days
Number of Stimulation Days
DaysFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Number of Stimulation Days10.4 ± 1.98.8 ± 1.8
Statistical analysis
  • FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE) · ANOVA · p = <0.0001 · Difference: 1.56 · 95% CI 1.19 to 1.92ANOVA model with treatment, age strata, and AMH group as factors.
SecondaryPositive Beta Human Chorionic Gonadotropin (βhCG) Rate

Defined as positive serum βhCG test

Time frame:
13-15 days after transfer (up to approximately 1.5 months after start of stimulation)
Reported as:
Count of participants · Participants
Positive Beta Human Chorionic Gonadotropin (βhCG) Rate
ParticipantsFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Positive βhCG test9179
Negative βhCG test111125
Statistical analysis
  • FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE) · Regression, Logistic · p = 0.1579 · Difference: 6.99 · 95% CI -2.71 to 16.70Logistic regression model with treatment, age strata, and AMH group as factors.
SecondaryImplantation Rate

Defined as the number of gestational sacs after transfer divided by number of blastocysts transferred

Time frame:
5-6 weeks after transfer (up to approximately 2.5 months after start of stimulation)
Reported as:
Number · Embryos
Implantation Rate
EmbryosFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Implantation Rate8268
SecondaryClinical Pregnancy Rate

Defined as at least one gestational sac

Time frame:
5-6 weeks after transfer (up to approximately 2.5 months after start of stimulation)
Reported as:
Count of participants · Participants
Clinical Pregnancy Rate
ParticipantsFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Positive8168
Negtaive121136
Statistical analysis
  • FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE) · Regression, Logistic · p = 0.1134 · Difference: 7.66 · 95% CI -1.82 to 17.14Logistic regression model with treatment, age strata, and AMH group as factors.
SecondaryVital Pregnancy Rate

Defined as at least one intrauterine gestational sac with fetal heart beat

Time frame:
5-6 weeks after transfer (up to approximately 2.5 months after start of stimulation)
Reported as:
Count of participants · Participants
Vital Pregnancy Rate
ParticipantsFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Positive7762
Negative125142
Statistical analysis
  • FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE) · Regression, Logistic · p = 0.0642 · Difference: 8.81 · 95% CI -0.52 to 18.14Logistic regression model with treatment, age strata, and AMH group as factors.
SecondaryOngoing Pregnancy Rate

At least one intrauterine viable fetus

Time frame:
10-11 weeks after transfer (up to approximately 4 months after start of stimulation)
Reported as:
Count of participants · Participants
Ongoing Pregnancy Rate
ParticipantsFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Positive7360
Negative129144
Statistical analysis
  • FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE) · Regression, Logistic · p = 0.1002 · Difference: 7.74 · 95% CI -1.49 to 16.97Logistic regression model with treatment, age strata, and AMH group as factors.
SecondaryOngoing Implantation Rate

Defined as number of intrauterine viable fetuses divided by the number of blastocysts transferred

Time frame:
10-11 weeks after transfer (up to approximately 4 months after start of stimulation)
Reported as:
Number · Embryos
Ongoing Implantation Rate
EmbryosFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Ongoing Implantation Rate7460
SecondaryProportion of Subjects With Early OHSS (Including OHSS of Moderate/Severe Grade)

Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe.

Time frame:
Up to 9 days after triggering of final follicular maturation
Reported as:
Count of participants · Participants
Proportion of Subjects With Early OHSS (Including OHSS of Moderate/Severe Grade)
ParticipantsFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Proportion of Subjects With Early OHSS (Including OHSS of Moderate/Severe Grade)85
SecondaryProportion of Subjects With Late OHSS (Including OHSS of Moderate/Severe Grade)

Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe.

Time frame:
>9 days after triggering of final follicular maturation
Reported as:
Count of participants · Participants
Proportion of Subjects With Late OHSS (Including OHSS of Moderate/Severe Grade)
ParticipantsFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Proportion of Subjects With Late OHSS (Including OHSS of Moderate/Severe Grade)46
SecondaryFrequency of Adverse Events

Any untoward medical occurrence

Time frame:
From time of signing informed consent until the end-of-trial (approximately 7 months)
Reported as:
Count of participants · Participants
Frequency of Adverse Events
ParticipantsFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Frequency of Adverse Events112109
SecondaryIntensity of Adverse Events

Categorized as mild, moderate or severe

Time frame:
From time of signing informed consent until the end-of-trial (approximately 7 months)
Reported as:
Number · Percentage of participants
Intensity of Adverse Events
Percentage of participantsFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Mild adverse events42.641.7
Moderate adverse events18.816.7
Severe adverse events4.03.4
SecondaryTechnical Malfunctions of the Pre-filled Injection Pen

Incidences of technical malfunctions of the pre-filled injection pen were recorded

Time frame:
Up to 20 days
Reported as:
Count of participants · Participants
Technical Malfunctions of the Pre-filled Injection Pen
ParticipantsFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Technical Malfunctions of the Pre-filled Injection Pen20

Adverse events

Collected over Adverse events were recorded from signing of the informed consent until end-of-trial (approximately 7 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FE 999049 + GnRH Agonist (GONAPEPTYL)0/202 (0%)4/202 (2%)68/202 (33.7%)
FE 999049 + GnRH Antagonist (CETROTIDE)0/204 (0%)6/204 (2.9%)69/204 (33.8%)
Most frequent serious events
Most frequent serious events
EventFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
Ovarian hyperstimulation syndromeReproductive system and breast disorders2/2024/204
AppendicitisInfections and infestations1/2020/204
Bacterial abdominal infectionInfections and infestations1/2020/204
Hyperemesis gravidarumPregnancy, puerperium and perinatal conditions0/2021/204
Adnexal torsionReproductive system and breast disorders0/2021/204
Most frequent other events
Most frequent other events
EventFE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)
HeadacheNervous system disorders27/20229/204
Procedural painInjury, poisoning and procedural complications20/20212/204
Pelvic painReproductive system and breast disorders14/20211/204
Ovarian hyperstimulation syndromeReproductive system and breast disorders12/20211/204
Biochemical pregnancyPregnancy, puerperium and perinatal conditions10/20211/204

Baseline characteristics

Age, Continuous
Age, Continuous(years)FE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)Total
Mean32.3 ± 4.432.4 ± 4.232.3 ± 4.3
Age, Customized
Age, Customized(Participants)FE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)Total
<35 years143141284
35-37 years474895
38-40 years302656
Sex: Female, Male
Sex: Female, Male(Participants)FE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)Total
Female220215435
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)Total
Hispanic or Latino91019
Not Hispanic or Latino211205416
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)Total
American Indian or Alaska Native022
Asian9817
Native Hawaiian or Other Pacific Islander011
Black or African American325
White208202410
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)FE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)Total
Austria293160
Netherlands312657
Norway117114231
Denmark151631
Italy91221
Israel131225
Switzerland6410
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)FE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH Antagonist (CETROTIDE)Total
Mean24.36 ± 3.5024.39 ± 3.5524.37 ± 3.52
08

Study locations

16 sites
  • Das Kinderwunsch Institut Schenk GmbH
    Dobl, Austria
  • Kepler University Hospital Linz
    Linz, Austria
  • Kinderwunschzentrum Goldenes Kreuz Privatklinik
    Vienna, Austria
  • Rigshospitalet
    Copenhagen, Denmark
  • Hillel Yafe Medical Center
    Hadera, Israel
  • Shaare Zedek Medical Center
    Jerusalem, Israel
  • Beilinson Hospital Rabin Medical Center
    Petah tikva, Israel
  • Sourasky Medical Center
    Tel Aviv, Israel
  • Dipartimento della Donna, del bambino e delle malattie urologiche
    Bologna, Italy
  • European Hospital
    Roma, Italy
  • St. Elisabeth Ziekenhuis
    Tilburg, Netherlands
  • Isala Fertility Center
    Zwolle, Netherlands
  • Oslo University Hospital
    Oslo, Norway
  • Sykehuset Telemark HF
    Porsgrunn, Norway
  • Medicus AS
    Trondheim, Norway
  • Gyn-A.R.T. AG
    Zürich, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Feb 2022, 33 months.

Results were first posted in May 2024, 2 years 2 months after primary completion.

Of 28 phase 3 interventional studies under Infertility, Female, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 33 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2019
First posted
Jan 18, 2019
StartActual
Apr 29, 2019
Primary completionActual
Feb 16, 2022
CompletionActual
Feb 16, 2022
Results first posted
May 13, 2024
Last update
May 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03809429
Responsible party
Sponsor
First posted
Jan 18, 2019
Start date
Apr 29, 2019
Primary completion
Feb 16, 2022
Completion
Feb 16, 2022
Results posted
May 13, 2024
Last update
May 13, 2024

Study contacts

Global Clinical Compliance
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Follitropin delta · Gonadotropin-releasing Hormone Analog

Start the discussion